Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Loman

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Microbial & Comparative Genomics|September 30, 2000
Sequencing of the Francisella tularensis strain Schu 4 genome reveals the shikimate and purine metabolic pathways, targets for the construction of a rationally attenuated auxotrophic vaccineJ Karlsson, R G Prior, K Williams, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 20, 2016
Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somaticC Winter, M P Nilsson, E Olsson, et al.
The New England Journal of Medicine|February 24, 2001
Gene-expression profiles in hereditary breast cancerI Hedenfalk, D Duggan, Y Chen, et al.
American Journal of Human Genetics|April 5, 2003
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studiesA Antoniou, P D P Pharoah, S Narod, et al.
British Journal of Cancer|March 24, 2011
Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2A Osorio, R L Milne, R Alonso, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2022
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancerC E Geyer, J E Garber, R D Gelber, et al.
British Journal of Cancer|June 7, 2012
Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter studyA Jakubowska, D Rozkrut, A Antoniou, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Microbial & Comparative Genomics|September 30, 2000
Sequencing of the Francisella tularensis strain Schu 4 genome reveals the shikimate and purine metabolic pathways, targets for the construction of a rationally attenuated auxotrophic vaccineJ Karlsson, R G Prior, K Williams, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 20, 2016
Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somaticC Winter, M P Nilsson, E Olsson, et al.
The New England Journal of Medicine|February 24, 2001
Gene-expression profiles in hereditary breast cancerI Hedenfalk, D Duggan, Y Chen, et al.
American Journal of Human Genetics|April 5, 2003
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studiesA Antoniou, P D P Pharoah, S Narod, et al.
British Journal of Cancer|March 24, 2011
Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2A Osorio, R L Milne, R Alonso, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2022
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancerC E Geyer, J E Garber, R D Gelber, et al.
British Journal of Cancer|June 7, 2012
Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter studyA Jakubowska, D Rozkrut, A Antoniou, et al.
Pageof 4